# Evaluation of Efficacy and Safety of Topical Cannabidiol (Canvert-M Produced by Alasht Pharmed co. Iran) in the Treatment of Migraine Attacks

> **NCT07093138** · PHASE4 · RECRUITING · sponsor: **Alasht Pharmed** · enrollment: 30 (estimated)

## Conditions studied

- Migraine Disorders

## Interventions

- **COMBINATION_PRODUCT:** Canvert-M (Produced by Alasht Pharmed co. Iran)

## Key facts

- **NCT ID:** NCT07093138
- **Lead sponsor:** Alasht Pharmed
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-16
- **Primary completion:** 2025-09-16
- **Final completion:** 2025-09-16
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07093138

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07093138, "Evaluation of Efficacy and Safety of Topical Cannabidiol (Canvert-M Produced by Alasht Pharmed co. Iran) in the Treatment of Migraine Attacks". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07093138. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*